Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

Biogen has received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment for moderate or severe postpartum depression (PPD) in women.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...

Takeda and Innovent have closed their global partnership for next-generation IO and ADC therapies after fulfilment of ...

Pfizer is set to cut several jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Formycon and Zydus Lifesciences have entered into an exclusive licensing and supply agreement for FYB206 in the US and Canada ...

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.